14930-96-2
基本信息
松胞菌素B
細(xì)胞松馳素B
細(xì)胞松弛素B
細(xì)胞松弛素 B
細(xì)胞分裂抑素B
細(xì)胞松弛素 B 來(lái)源于長(zhǎng)蠕孢菌
CYTOCHALASIN B 細(xì)胞松弛素B
細(xì)胞松弛素 B 來(lái)源于DRECHSLERA DEMATIOIDEA
-23-one
cytochalasin
CYTOCHALACINB
CYTOCHALICINB
CYTOCHALASIN B
CYTOCHALASIN B(RG)
(7s,13e,16r,20r,21e)-0-phenyl
CYTOCHALASIN B SYNTHETIC >97%
9r,12as,13s,15s,15as,16as,18as)-5
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
應(yīng)用領(lǐng)域
常見問(wèn)題列表
細(xì)胞松弛素B在細(xì)胞內(nèi)同微絲的正端結(jié)合, 并引起F-肌動(dòng)蛋白解聚,阻斷亞基的進(jìn)一步聚合。當(dāng)將細(xì)胞松弛素加入到活細(xì)胞后,肌動(dòng)蛋白纖維骨架消失,使動(dòng)物細(xì)胞的各種活動(dòng)癱瘓, 包括細(xì)胞的移動(dòng)、吞噬作用、胞質(zhì)分裂等。
Kd: 2.2 nM (F-actin, with Mg 2+ ), 1.4 nM (F-actin, with Mg 2+ /K + )
Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, inhibits the enlongation and shortening of actin filaments, with K d s of 2.2 nM and 1.4 nM for F-actin in the presence of MgCl 2 (2 mM) or MgCl 2 (2 mM) plus KCl, respectively. Cytochalasin B (0.1-10 μM) shows inhibitory effect on multiple murine cancer cell lines, with IC 50 s of 2.56 μM (M109c), 10.46 μM (B16BL6), 105.5 μM (P388/ADR), 51.9 μM (P388/S) and IC 80 s of 12.23 μM (M109c), 44.86 μM (B16BL6), 188.4 μM (P388/ADR), 84.1 μM (P388/S) after treatment for 3 h, with IC 50 s of 0.25 μM (M109c), 0.37 μM (B16F10), 0.87 μM (B16BL6), and IC 80 s of 0.75 μM (M109c), 1.21 μM (B16F10), 10.41 μM (B16BL6) after treatment for 4 days. Cytochalasin B (6 μM) increases the myofibrillar fragmentation index (MFI), which is attributed to the intensely breaking of myofibrillar proteins into short segments. Cytochalasin B also accelerates the disruption of actin filaments. In addition, Cytochalasin B accelerates the transformation from F-actin to G-actin, lowering the content of F-actin and significantly increasing G-actin bands during postmortem conditioning.
Cytochalasin B (10, 25, 50 mg/kg, i.p.) dose-dependently increases the life expectancy of Balb/c mice bearing with P388/ADR leukemias. Cytochalasin B at 50 mg/kg produces 10 % long-term survival in the multidrug resistant P388/ADR cohort, and 40 % long-term survival in the drug sensitive P388/S cohort.